Article
Oncology
Gennady Bratslavsky, Stephanie Gleicher, Joseph M. Jacob, Thomas H. Sanford, Oleg Shapiro, Dimitra Bourboulia, Laurie M. Gay, Julie Andrea Elvin, Jo-Anne Vergilio, James Suh, Shakti Ramkissoon, Eric Allan Severson, Jonathan Keith Killian, Alexa Betzig Schrock, Jon H. Chung, Vincent A. Miller, Mehdi Mollapour, Jeffrey S. Ross
Summary: The study found that genomic alteration patterns in collecting duct carcinoma (CDC) and renal medullary carcinoma (RMC) differ significantly from clear cell renal cell carcinoma (CCRCC). Targeted therapies for CDC and RMC appear limited, with rare opportunities to target alterations in receptor tyrosine kinase and MTOR pathways. Similarly, the low TMB and absence of MSI-High status in CDC and RMC suggest resistance to immunotherapies.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
(2021)
Article
Pathology
Daisuke Kiyozawa, Kenichi Kohashi, Dai Takamatsu, Shinya Umekita, Masatoshi Eto, Mitsuru Kinjo, Kenichi Nishiyama, Kenichi Taguchi, Yumi Oshiro, Yusuke Kuboyama, Yoshinao Oda
Summary: The study found differences in the tumor microenvironment and IL-8 expression between CDC and FH-deficient RCC, suggesting IL-8 as a potential therapeutic target for treating CDC.
JOURNAL OF CLINICAL PATHOLOGY
(2022)
Article
Oncology
Zoe Guillaume, Emeline Colomba, Jonathan Thouvenin, Carolina Saldana, Luca Campedel, Clement Dumont, Brigitte Laguerre, Denis Maillet, Cecile Vicier, Frederic Rolland, Delphine Borchiellini, Philippe Barthelemy, Laurence Albiges, Edouard Auclin, Matthieu Roulleaux Dugage, Stephane Oudard, Constance Thibault
Summary: Collecting duct carcinoma (CDC) and renal medullary carcinoma (RMC) are rare subtypes of kidney cancer with poor prognosis in the metastatic setting. Treatments after first-line chemotherapy showed very low antitumor activity in mCDC/RMC, highlighting the urgent need for a better understanding of the biology of these rare tumors.
Article
Oncology
Zoe Guillaume, Yves Allory, Edouard Auclin, Claire Gervais, Marie Auvray, Adrien Rochand, Arnaud Mejean, Francois Audenet, Yann-Alexandre Vano, Stephane Oudard, Constance Thibault
Summary: Collecting duct carcinoma and renal medullary carcinoma are very rare and aggressive renal cancers that are less responsive to conventional treatments. Polychemotherapy based on platinum salts is currently the most widely used treatment at the metastatic stage. New treatments such as anti-angiogenic TKIs, immunotherapy, and targeted therapies offer new possibilities for management. Evaluating the response to these treatments is essential, and this article reviews the current management strategies and studies on recent treatments for these cancers.
BULLETIN DU CANCER
(2023)
Article
Biochemistry & Molecular Biology
Wouter H. van Megen, Esra Canki, Vera H. A. Wagenaar, Charlotte R. M. M. van Waes, Dorien J. M. Peters, Jenny Van Asbeck-Van der Wijst, Joost G. J. Hoenderop
Summary: The flow rate of pro-urine in the kidney can activate mechanosensitive pathways, leading to ATP release. This study investigates the mechanisms underlying flow-induced ATP release in the collecting duct and its relation to ADPKD.
Article
Oncology
Qingqiang Zhu, Jun Ling, Jing Ye, Wenrong Zhu, Jingtao Wu, Wenxin Chen
Summary: This study characterized the clinical and CT imaging features of 33 patients with CRCC and 13 patients with CCDC. The distinguishing features of CRCC and CCDC on CT and MR images included differences in calcifications, capsule signs, metastasis, and signal intensity, which may aid in differentiation between the two renal tumor types.
Article
Multidisciplinary Sciences
Xiaoyuan Qian, Junlai Wan, Yuanzhong Tan, Zhenrui Liu, Ying Zhang
Summary: This study investigated the prognostic factors and the impact of cytoreductive nephrectomy (CNx) on the outcomes in patients with metastatic renal collecting duct carcinoma (CDC). It found that CNx improved the prognosis of metastatic CDC patients, and surgical resection of visible lesions and suitable chemotherapy were identified as alternative treatment strategies.
SCIENTIFIC REPORTS
(2022)
Article
Oncology
Liwei Wei, Yongdi Huang, Zheng Chen, Jinhua Li, Guangyi Huang, Xiaoping Qin, Lihong Cui, Yumin Zhuo
Summary: This study aimed to investigate the clinical and non-clinical characteristics affecting the prognosis of renal collecting duct carcinoma (CDC) and develop an accurate prognostic model. The machine learning model showed the best predictive performance and could potentially assist clinicians in making clinical decisions for CDC patients.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Constance Thibault, Aude Flechon, Laurence Albiges, Charlotte Joly, Philippe Barthelemy, Marine Gross-Goupil, Christine Chevreau, Elodie Coquan, Frederic Rolland, Brigitte Laguerre, Gwenaelle Gravis, Nicolas Pecuchet, Reza-Thierry Elaidi, Marc-Olivier Timsit, Meryem Brihoum, Edouard Auclin, Aurelien de Reynies, Yves Allory, Stephane Oudard
Summary: This study evaluated the safety and efficacy of bevacizumab in combination with chemotherapy for metastatic renal medullary carcinoma and collecting duct carcinoma. The results showed that the addition of bevacizumab did not provide additional benefits and was associated with higher toxicity. Therefore, chemotherapy remains a treatment option for patients with these types of cancers.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Xiaoyuan Qian, Jinzhou Xu, Chenqian Liu, Mingliang Zhong, Senyuan Hong, Can Qian, Jianning Zhu, Jiaqiao Zhang, Shaogang Wang
Summary: This study used SEER database to investigate the prognostic factors and treatment modalities for renal collecting duct carcinoma (CDC). The results showed that CDC is a rare and malignant disease with poor prognosis. Surgery and chemotherapy were found to have a positive impact on the survival of patients.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Andrea Panunzio, Gabriele Sorce, Stefano Tappero, Lukas Hohenhorst, Cristina Cano Garcia, Mattia Piccinelli, Zhe Tian, Alessandro Tafuri, Ottavio De Cobelli, Felix K. H. Chun, Derya Tilki, Carlo Terrone, Alberto Briganti, Anil Kapoor, Fred Saad, Shahrokh F. Shariat, Maria Angela Cerruto, Alessandro Antonelli, Pierre I. Karakiewicz
Summary: Large-scale, contemporary, controlled analysis of mortality in metastatic collecting duct renal carcinoma are scarce. However, combination of cytoreductive nephrectomy and systemic therapy provide the lowest mortality rates in these patients.
CLINICAL GENITOURINARY CANCER
(2023)
Article
Oncology
Zhuoer Xie, Siddhartha Yadav, Christine M. Lohse, John C. Cheville, Lance C. Pagliaro, Paras H. Shah, Stephen A. Boorjian, Houston Thompson, Bradley C. Leibovich, Brian A. Costello
Summary: Collecting duct carcinoma is a rare type of kidney cancer that mainly affects males with a median age of 57 years old. Most patients present with high-grade disease at the time of nephrectomy, and early local recurrence and distant metastases are common. However, some patients with small tumors may benefit from nephrectomy in the long term.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
(2022)
Article
Pathology
Daisuke Kiyozawa, Kenichi Kohashi, Dai Takamatsu, Takeshi Iwasaki, Daiki Shibata, Takumi Tomonaga, Yuki Tateishi, Masatoshi Eto, Mitsuru Kinjo, Kenichi Nishiyama, Kenichi Taguchi, Yumi Oshiro, Yusuke Kuboyama, Mitsuko Furuya, Yoshinao Oda
Summary: Collecting duct carcinoma (CDC) is a rare subset of high-grade renal cell carcinoma (RCC), and there is overlap in the morphology with other renal tumors. This study reclassified invasive/infiltrating high-grade RCC and found that a combination of immunohistochemistry and molecular biological techniques is necessary for the diagnosis of invasive/infiltrating high-grade RCC.
Article
Cell Biology
Anastasia Sudarikova, Mikhail Fomin, Regina F. Sultanova, Ying Zhao, Samantha Perez, Mark Domondon, Margarita Shamatova, Daria Lysikova, Denisha R. Spires, Daria Ilatovskaya
Summary: This study investigates the role of histamine-related pathways in the kidney, specifically in the collecting duct cells. The findings demonstrate the expression of histamine receptors and enzymes responsible for histamine metabolism and synthesis in these cells, as well as the effects of histamine on intracellular calcium and cAMP levels. Additionally, histamine inhibits the activity of epithelial sodium channels and decreases the expression of alpha ENaC. These results suggest potential implications of histamine in inflammation-related renal conditions.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
(2022)
Article
Physiology
Juliano Zequini Polidoro, Nancy Amaral Reboucas, Adriana Castello Costa Girardi
Summary: The study demonstrates that ATRAP attenuates Ang II-induced inhibition of ROMK in collecting duct cells by reducing c-Src activation and blocking ROMK internalization.
FRONTIERS IN PHYSIOLOGY
(2021)